JNJ FDA calendar & decision history Johnson & Johnson · no upcoming catalyst on file · 17 past FDA decisions
FDA decision history (17) May 29, 2026✓ Approved TREMFYA (guselkumab) Mar 18, 2026✓ Approved ICOTYDE (icotrokinra) Mar 5, 2026✓ Approved TECVAYLI (teclistamab-cqyv) an Feb 17, 2026✓ Approved FDA decision Jan 27, 2026✓ Approved FDA decision Dec 18, 2025✓ Approved FDA decision Dec 15, 2025✓ Approved FDA decision Nov 7, 2025✓ Approved FDA decision Nov 6, 2025✓ Approved FDA decision Sep 29, 2025✓ Approved FDA decision Sep 19, 2025✓ Approved FDA decision Sep 9, 2025✓ Approved FDA decision Jun 13, 2025✕ CRL FDA decision Apr 30, 2025✓ Approved FDA decision Apr 24, 2025✕ CRL FDA decision Mar 20, 2025✓ Approved FDA decision Jan 21, 2025✓ Approved FDA decision See the full 2026 PDUFA calendar → This page aggregates JNJ's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent service; "FDA", "PDUFA", and all company, drug, and ticker names are used descriptively and remain the property of their owners. Informational and educational only — not investment advice. Data and historical statistics only; no trade recommendations and no individual-drug approval probabilities. Verify every date and outcome against primary FDA / SEC / company filings. © 2026 pdufa.bio